RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
Recruiting · NCT06409832 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Florence
View the official record on ClinicalTrials.gov →Interventions studied
Rimegepant 75 mg
What this trial is about
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Diagnosis of migraine without aura or migraine with aura, according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);
- At least 4 monthly migraine days;
- Good compliance to study procedures;
- Availability of headache diary at least of the preceding months before enrollment.
Exclusion criteria
- Subjects with contraindications for use of gepants;
- Diagnosis of chronic migraine
- Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
- medical comorbidities that could interfere with study results;
- Pregnancy and breastfeeding.
- Changes in preventive treatments in the month before the first administration of rimegepant
Where it is running
2 locations listed.
- SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi - Florence, Florence, Italy
- IRCCS National Neurological Institute "C. Mondino" Foundation - Pavia, Pavia, Italy